Herantis Pharma Oyj Beheer

Beheer criteriumcontroles 2/4

De CEO Herantis Pharma Oyj is Antti Vuolanto, benoemd in Jul2022, heeft een ambtstermijn van 2.33 jaar. bezit rechtstreeks 0.012% van de aandelen van het bedrijf, ter waarde € 3.30K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 3.6 jaar.

Belangrijke informatie

Antti Vuolanto

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.3yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	4.1yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

CEO

Antti Vuolanto (49 yo)

2.3yrs

Tenure

Dr. Antti Vuolanto, D.Sc. (Tech) serves as Chief Executive Officer of Herantis Pharma Oyj since July 2022. He served as Chief Operating Officer at Herantis Pharma Oyj since February 2018. Dr. Vuolanto serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Antti Vuolanto	Chief Executive Officer	2.3yrs	geen gegevens	0.012% € 3.3k
Tone Kvale	Chief Financial Officer	4.1yrs	geen gegevens	0.056% € 15.8k
Henri Huttunen	Chief Scientific Officer	14.8yrs	geen gegevens	0.40% € 112.3k
Jani Koskinen	Head of CMC	no data	geen gegevens	geen gegevens
Outi Lahdenperä	Chief Medical Ofcer	no data	geen gegevens	geen gegevens
Charlotte Videbaek	Clinical Consultant	no data	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HRTIS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aki Prihti	Director	10.8yrs	geen gegevens	0.0079% € 2.3k
Anders Pedersen	Chairman of Scientific Advisory Board	3.2yrs	geen gegevens	geen gegevens
Timo Veromaa	Independent Chairman of the Board	12.8yrs	geen gegevens	0.076% € 21.5k
Mats Thoren	Director	4.6yrs	geen gegevens	geen gegevens
Frans Wuite	Director	10.8yrs	geen gegevens	0.14% € 38.5k
Alberto Espay	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Hilde Furberg	Director	3.6yrs	geen gegevens	0.0099% € 2.8k
David Dexter	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Daniele Bravi	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HRTIS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Herantis Pharma Oyj Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Oyj Announces Nomination Committee Appointments

Recent updates

Herantis Pharma Plc Starts Dosing of HER-096 in the Part 1 of the Phase 1b Clinical Trial

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd